All Stories

  1. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole‐induced hypergastrinaemia in healthy subjects

    Article • British Journal of Clinical Pharmacology, April 2015, Wiley

    Dr Malcolm Boyce

  2. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study

    Article • International Journal of General Medicine, December 2013, Taylor & Francis

    Dr Malcolm Boyce

  3. Correction: Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

    Article • PLoS ONE, November 2013, PLOS

    Dr Malcolm Boyce

  4. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose‐dependent, persistent inhibition of the responses to pentagastrin in healthy subjects

    Article • British Journal of Clinical Pharmacology, October 2013, Wiley

    Dr Malcolm Boyce

  5. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects

    Article • British Journal of Clinical Pharmacology, October 2013, Wiley

    Dr Malcolm Boyce

  6. Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

    Article • PLoS ONE, October 2013, PLOS

    Dr Malcolm Boyce

  7. Biological therapies: a long way on from Jenner

    Article • British Journal of Clinical Pharmacology, July 2013, Wiley

    Dr Malcolm Boyce

  8. The Gastrin Receptor Antagonist Netazepide (YF476) Prevents Oxyntic Mucosal Inflammation Induced by Helicobacter Pylori Infection in Mongolian Gerbils

    Article • Helicobacter, July 2013, Wiley

    Dr Malcolm Boyce

  9. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, November 2012, Springer Science + Business Media

    Dr Malcolm Boyce

  10. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

    Article • Alimentary Pharmacology & Therapeutics, November 2012, Wiley

    Dr Malcolm Boyce

  11. The gastrin receptor antagonist YF476 prevents oxyntic mucosal inflammation due to Helicobacter pylori infection in Mongolian gerbils

    Article • Regulatory Peptides, August 2012, Elsevier

    Dr Malcolm Boyce

  12. OC-097 The novel gastrin/CCK2 receptor antagonist YF476 induces clinical responses and is well tolerated in patients with type I gastric neuroendocrine tumours

    Article • Gut, May 2012, BMJ

    Dr Malcolm Boyce

  13. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects

    Article • Alimentary Pharmacology & Therapeutics, May 2012, Wiley

    Dr Malcolm Boyce

  14. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development

    Article • Regulatory Peptides, June 2010, Elsevier

    Dr Malcolm Boyce

  15. S1084 Effects of the Gastrin Antagonist, YF476, On Gastric Acid Secretion Models Using Gastric Fistula Dogs

    Article • Gastroenterology, April 2008, Elsevier

    Dr Malcolm Boyce